-
1
-
-
73349099345
-
Insulin therapy and quality of life. A review
-
Pouwer F, Hermanns N. Insulin therapy and quality of life. A review. Diabet. Metab. Res. Rev. 2009; 25(Suppl. 1): S4-10.
-
(2009)
Diabet. Metab. Res. Rev.
, vol.25
, pp. S4-10
-
-
Pouwer, F.1
Hermanns, N.2
-
2
-
-
0029147687
-
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
-
Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabet. Res. Clin. Prac. 1995; 28: 103-17.
-
(1995)
Diabet. Res. Clin. Prac.
, vol.28
, pp. 103-117
-
-
Ohkubo, Y.1
Kishikawa, H.2
Araki, E.3
-
3
-
-
0032511583
-
Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
4
-
-
0032742992
-
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
-
Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94.
-
(1999)
J Clin Invest
, vol.104
, pp. 787-794
-
-
Weyer, C.1
Bogardus, C.2
Mott, D.M.3
Pratley, R.E.4
-
5
-
-
0035340067
-
Oral agents in the management of type 2 diabetes mellitus
-
Luna B, Feinglos M. Oral agents in the management of type 2 diabetes mellitus. Am. Fam. Physician 2001; 63: 1747-56.
-
(2001)
Am. Fam. Physician
, vol.63
, pp. 1747-1756
-
-
Luna, B.1
Feinglos, M.2
-
6
-
-
84873029199
-
AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: A summary of the key findings
-
Bennett WL, Balfe LM, Faysal JM. AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: A summary of the key findings. J. Manag. Care Pharm. 2012; 1(Suppl. A): s3-20.
-
(2012)
J. Manag. Care Pharm.
, vol.1
, pp. s3-20
-
-
Bennett, W.L.1
Balfe, L.M.2
Faysal, J.M.3
-
7
-
-
0028874605
-
-
The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510-18.
-
(1995)
Diabetes Care
, vol.18
, pp. 1510-1518
-
-
-
8
-
-
60449089649
-
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy
-
Nathan DM, Holman RR, Buse JB et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009; 32: 193-203.
-
(2009)
Diabetes Care
, vol.32
, pp. 193-203
-
-
Nathan, D.M.1
Holman, R.R.2
Buse, J.B.3
-
9
-
-
0032983666
-
Glycemic control with diet, sulfonylurea, metformin, or insulin in Patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)
-
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in Patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
-
(1999)
JAMA
, vol.281
, pp. 2005-2012
-
-
Turner, R.C.1
Cull, C.A.2
Frighi, V.3
Holman, R.R.4
-
10
-
-
0347133334
-
Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
-
Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
-
(2004)
JAMA
, vol.291
, pp. 335-342
-
-
Saydah, S.H.1
Fradkin, J.2
Cowie, C.C.3
-
11
-
-
78651406659
-
SGLT2 mediates glucose reabsorption in the early proximal tubule
-
Vallon V, Platt KA, Cunard R et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 2011; 22: 104-12.
-
(2011)
J. Am. Soc. Nephrol.
, vol.22
, pp. 104-112
-
-
Vallon, V.1
Platt, K.A.2
Cunard, R.3
-
12
-
-
34547449243
-
Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells
-
Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells. Kidney Int. 2007; 72: s27-35.
-
(2007)
Kidney Int.
, vol.72
, pp. s27-s35
-
-
Lee, Y.J.1
Lee, Y.J.2
Han, H.J.3
-
13
-
-
48249146624
-
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
-
Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-9.
-
(2008)
Diabetes
, vol.57
, pp. 1723-1729
-
-
Han, S.1
Hagan, D.L.2
Taylor, J.R.3
-
14
-
-
0032850016
-
T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes
-
Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-800.
-
(1999)
Diabetes
, vol.48
, pp. 1794-1800
-
-
Oku, A.1
Ueta, K.2
Arakawa, K.3
-
15
-
-
77953857048
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial
-
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-33.
-
(2010)
Lancet
, vol.375
, pp. 2223-2233
-
-
Bailey, C.J.1
Gross, J.L.2
Pieters, A.3
Bastien, A.4
List, J.F.5
-
16
-
-
84862875221
-
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy
-
Rosenstock J, Salsali A, Vico M, List JF, Wei L. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-8.
-
(2012)
Diabetes Care
, vol.35
, pp. 1473-1478
-
-
Rosenstock, J.1
Salsali, A.2
Vico, M.3
List, J.F.4
Wei, L.5
-
17
-
-
84861781220
-
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
-
Rosenstock J, Usiskin K, Aggarwal N et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-8.
-
(2012)
Diabetes Care
, vol.35
, pp. 1232-1238
-
-
Rosenstock, J.1
Usiskin, K.2
Aggarwal, N.3
-
18
-
-
84876344111
-
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study
-
Wilding JPH, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study. Diabetes Obes. Metab. 2013; 15: 403-9.
-
(2013)
Diabetes Obes. Metab.
, vol.15
, pp. 403-409
-
-
Wilding, J.P.H.1
Ferrannini, E.2
Fonseca, V.A.3
Wilpshaar, W.4
Dhanjal, P.5
Houzer, A.6
-
19
-
-
84877922239
-
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data
-
Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol. Ther. 2013; 139: 51-9.
-
(2013)
Pharmacol. Ther.
, vol.139
, pp. 51-59
-
-
Kurosaki, E.1
Ogasawara, H.2
-
20
-
-
84860492610
-
Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
-
Imamura M, Nakanishi K, Suzuki T et al. Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem. 2012; 20: 3263-79.
-
(2012)
Bioorg. Med. Chem.
, vol.20
, pp. 3263-3279
-
-
Imamura, M.1
Nakanishi, K.2
Suzuki, T.3
-
21
-
-
84866541730
-
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice
-
Tahara A, Kurosaki E, Yokono M et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J. Pharmacol. Sci. 2012; 120: 36-44.
-
(2012)
J. Pharmacol. Sci.
, vol.120
, pp. 36-44
-
-
Tahara, A.1
Kurosaki, E.2
Yokono, M.3
-
22
-
-
84861544136
-
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
-
Tahara A, Kurosaki E, Yokono M et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 2012; 385: 423-36.
-
(2012)
Naunyn-Schmiedeberg's Arch. Pharmacol.
, vol.385
, pp. 423-436
-
-
Tahara, A.1
Kurosaki, E.2
Yokono, M.3
-
23
-
-
84885476895
-
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
-
Tahara A, Kurosaki E, Yokono M et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 2013; 715: 246-55.
-
(2013)
Eur. J. Pharmacol.
, vol.715
, pp. 246-255
-
-
Tahara, A.1
Kurosaki, E.2
Yokono, M.3
-
24
-
-
58149295120
-
Nutritional regulation of glucagon-like peptide-1 secretion
-
Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J. Physiol. 2009; 587: 27-32.
-
(2009)
J. Physiol.
, vol.587
, pp. 27-32
-
-
Tolhurst, G.1
Reimann, F.2
Gribble, F.M.3
-
25
-
-
0028838030
-
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients
-
Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-26.
-
(1995)
Digestion
, vol.56
, pp. 117-126
-
-
Herrmann, C.1
Göke, R.2
Richter, G.3
Fehmann, H.C.4
Arnold, R.5
Göke, B.6
-
26
-
-
0014743725
-
General survey of diabetic features of yellow KK mice
-
Iwatsuka H, Shino A, Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol. Jpn. 1970; 17: 23-35.
-
(1970)
Endocrinol. Jpn.
, vol.17
, pp. 23-35
-
-
Iwatsuka, H.1
Shino, A.2
Suzuoki, Z.3
-
27
-
-
0029886788
-
Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects
-
Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 1996; 45: 731-7.
-
(1996)
Metabolism
, vol.45
, pp. 731-737
-
-
Shinozaki, K.1
Suzuki, M.2
Ikebuchi, M.3
Hirose, J.4
Hara, Y.5
Harano, Y.6
-
28
-
-
0032465376
-
A genetic non-insulin dependent diabetic mice KK-Ay mice, is elevated alpha-glucosyldisaccharide digestive/absorptive capacity in small intestine
-
Miura T, Ishihara E, Ishida H, Seino Y, Tanigawa K. A genetic non-insulin dependent diabetic mice KK-Ay mice, is elevated alpha-glucosyldisaccharide digestive/absorptive capacity in small intestine. Biomed. Res. 1998; 19: 335-8.
-
(1998)
Biomed. Res.
, vol.19
, pp. 335-338
-
-
Miura, T.1
Ishihara, E.2
Ishida, H.3
Seino, Y.4
Tanigawa, K.5
-
29
-
-
0026607265
-
Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression
-
Hofmann CA, Edwards CW III, Hillman RM, Colca JR. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinol 1992; 130: 735-40.
-
(1992)
Endocrinol
, vol.130
, pp. 735-740
-
-
Hofmann, C.A.1
Edwards III, C.W.2
Hillman, R.M.3
Colca, J.R.4
-
30
-
-
84865990718
-
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects
-
Smulders RA, Zhang W, Veltkamp SA et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes. Metab. 2012; 14: 937-43.
-
(2012)
Diabetes Obes. Metab.
, vol.14
, pp. 937-943
-
-
Smulders, R.A.1
Zhang, W.2
Veltkamp, S.A.3
-
31
-
-
84864602342
-
Combination treatment with ipragliflozin and metformin: A randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus
-
Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA. Combination treatment with ipragliflozin and metformin: A randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin. Ther. 2012; 34: 1761-71.
-
(2012)
Clin. Ther.
, vol.34
, pp. 1761-1771
-
-
Veltkamp, S.A.1
van Dijk, J.2
Collins, C.3
van Bruijnsvoort, M.4
Kadokura, T.5
Smulders, R.A.6
|